Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
Boston Globe: Top Places to Work in Massachusetts 2023
Nearly 76,000 workers at 347 companies responded to the survey questions rating their employers on leadership, values, training, benefits, and other metrics. The rankings are broken down into four size categories: small (50-99 employees); medium (100-249); large (250-999); and largest (1,000 or more).
Drug Hunter: KT-474 Brings IRAK4 Back: The First Clinically Active Bifunctional Degrader Outside Oncology
Kymera’s KT-474 is the first oral degrader to demonstrate activity in clinical trials outside cancer. Sanofi recently started a Ph. II trial with the molecule in AD, restoring life to IRAK4 as an immunology target.
Dermatology News: KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study
Kymera Therapeutics recently shared promising results from the phase 1 clinical trial of its lead program, KT-474, marking a significant milestone in the field of targeted protein degradation (TPD).
C&EN: Degrader progresses in clinical trials for skin conditions
Kymera Therapeutics’ degrader KT-474 has shown promise for treating two inflammatory skin conditions in an early clinical trial. The success suggests that these compounds could be used to treat nonlethal, chronic conditions, where there is a high bar for tolerability.
Talking Biotech: Therapeutics Controlling Protein Turnover – Dr. Juliet Williams
Cells have intricate mechanisms to remove damaged or mis-expressed proteins that could be deleterious to cellular function. This process is mediated by a process called ubiquitination, mediated by a special class of proteins called E3 ligases. Ubiquitin is the tag that’s added that signals that a protein should be moved to the biochemical garbage can. Dr. Juliet WIlliams of Kymera describes how their company has used modeling and A.I. to design molecular linkers that connect a protein that needs to be degraded with the machinery to tag it for destruction.
Watertown News: Watertown Life Science Company Entering Team in Jimmy Fund Walk
The company has a program called Kymera Cares, an effort that allows employees to give back, volunteer, and fundraise for organizations helping local communities throughout the greater Boston area as well as patients and their support systems.
OncLive: FDA Grants Fast Track Designation to KT-333 in R/R CTCL and PTCL
The FDA has granted fast track designation to KT-333 for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) and relapsed/refractory peripheral T-cell lymphoma (PTCL).
Pharmaceutical Business Review: Kymera Receives Fast Track Designation for KT-333
Kymera Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for KT-333 to treat Relapsed/Refractory (R/R) Cutaneous T-Cell Lymphoma (CTCL) and Peripheral T-Cell Lymphoma (PTCL).
Watertown News: Prospective Young Scientists Get a Look at a Real Lab at Watertown’s Kymera Therapeutics
A group of aspiring young scientists got a glimpse inside a Watertown company that does cutting-edge biopharmaceutical research.
BiotechTV: Kymera shows us the technologies that enable the development of protein degradation based medicines
Nello Mainolfi explains the concept of protein degradation and describes three key technologies that enable precision protein measurement